Home Page en

Malignant melanoma is the most dangerous of skin cancers and it’s a cancer that originates from melanocytes, cells responsible for the production of melanin.

The reading of the various pages of the website will help you to understand the various aspects of melanoma, while in the “Resources on melanoma” you will find information on the links, books, conferences and other useful information.

[widget widget_name=”avia_newsbox” widget_class_name=”newsbox” title=”Highlighted Articles” count=”10″ cat=”211″ excerpt=”display title and excerpt”]

Questo post è disponibile anche in: Italian

Melanoma

Ulceration, Breslow thickness and Clark level significantly predicted sentinel lymph node disease in patients with thin melanomas

Breslow thickness ≥ 0.75 mm, Clark level ≥ IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2%) occur in melanomas ≥ 0.75 mm, with 6.3% of these patients having SLN disease, whereas in melanomas < 0.75 mm, SLN metastasis rates are < 5%. By using a 5% metastasis risk threshold,

Lentigo Maligna Melanoma

A new study at Moffitt Cancer Center could offer hope to people with melanoma

Abstract from PLOS ONE: Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer  Paul Toomey,  Krithika Kodumudi, Amy Weber, Lisa Kuhn,  Ellen Moore, Amod A. Sarnaik, Shari Pilon-Thomas  Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine

GSK melanoma therapy Tafinlar cleared in EU

GSK melanoma therapy Tafinlar cleared in EU

GlaxoSmithKline plc [announced today that the U.S. Food and Drug Administration (FDA) has approved both TAFINLAR® (dabrafenib) and MEKINIST™ (trametinib). Tafinlar is indicated as a single-agent oral treatment for unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) in adult patients with BRAF

Human skin carcinoma arising from kidney transplant–derived tumor cells

Tumor cells with donor genotype have been identified in human skin cancer after allogeneic transplantation; however, the donor contribution to the malignant epithelium has not been established. Kidney transplant recipients have an increased risk of invasive skin squamous cell carcinoma (SCC), which is associated with accumulation of the tumor suppressor p53 and TP53 mutations. In